The ESMO-Magnitude of Clinical Benefit Scale has been enhanced to address critical aspects of modern oncology trials, such as novel study designs, quality of life and long-term survival benefits
In a study, a machine learning approach outperformed cancer-specific models and revealed universal biomarkers to guide end-of-life care decisions
Quality of life and pain management data adds to efficacy results of combining TTFields with gemcitabine and nab-paclitaxel as a potential new option of care
Antibody–drug conjugates may represent a step up from existing therapeutic options, but further optimisation and biomarker analyses are required.
Additional treatment targets and potentially repurposable agents were identified based on chemoradiotherapy response, which could now be explored for further validation.
Global cooperation is needed to improve trial design and expedite new treatments specifically in low- and middle-income countries
Findings from studies show that patient-centred evidence can inform decisions in early-phase cancer research
Artificial intelligence has entered drug discovery and development supporting target identification and validation, but challenges remain
Reflecting on her transatlantic journey from Italy to the United States of America, Prof. Marina Chiara Garassino shares the key lessons that continue to influence her leadership style
Study findings show that ctDNA is a stronger biomarker than carcinoembryonic antigen to select patients who may benefit from metastasis-directed therapy
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.